AVITA MED LTD/S (OTCMKTS:AVMXY) and Fennec Pharmaceuticals (NASDAQ:FENC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations and institutional ownership.
Earnings and Valuation
This table compares AVITA MED LTD/S and Fennec Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|AVITA MED LTD/S||$1.25 million||42.03||-$12.78 million||N/A||N/A|
|Fennec Pharmaceuticals||N/A||N/A||-$7.04 million||($0.47)||-14.89|
Institutional & Insider Ownership
47.8% of Fennec Pharmaceuticals shares are held by institutional investors. 9.9% of Fennec Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares AVITA MED LTD/S and Fennec Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|AVITA MED LTD/S||N/A||N/A||N/A|
This is a breakdown of recent ratings and recommmendations for AVITA MED LTD/S and Fennec Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|AVITA MED LTD/S||0||0||1||0||3.00|
AVITA MED LTD/S presently has a consensus price target of $65.00, indicating a potential upside of 3,815.66%. Fennec Pharmaceuticals has a consensus price target of $17.00, indicating a potential upside of 142.86%. Given AVITA MED LTD/S’s higher possible upside, analysts clearly believe AVITA MED LTD/S is more favorable than Fennec Pharmaceuticals.
Risk & Volatility
AVITA MED LTD/S has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of -0.23, meaning that its share price is 123% less volatile than the S&P 500.
AVITA MED LTD/S beats Fennec Pharmaceuticals on 5 of the 9 factors compared between the two stocks.
AVITA MED LTD/S Company Profile
Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products for the treatment of burns, chronic wounds, and aesthetics indications. The company's patented and proprietary collection and application technology provides treatment solutions derived from a patient's own skin. Its lead product, RECELL System, is used in the treatment of various skin defects, such as burns and plastic reconstructive procedures. The company also offers ReGenerCell for chronic wounds and ReNovaCell for the restoration of pigmentation. Avita Medical Limited is based in Valencia, California.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Receive News & Ratings for AVITA MED LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVITA MED LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.